Review: Prognostic value of C-reactive protein in patients with COVID-19

Home/Review: Prognostic value of C-reactive protein in patients with COVID-19

Review: Prognostic value of C-reactive protein in patients with COVID-19

Review: Prognostic value of C-reactive protein in patients with COVID-19

This study found that admission C-reactive protein (CRP) correlated with disease severity and tended to be a good predictor of adverse outcome.

  • Data of COVID-19 patients with clinical outcome in a designated hospital in Wuhan, China, were retrospectively collected and analyzed from Jan 30 to Feb 20, 2020
  • Out of 298 patients enrolled, 84 died and 214 recovered. Most non-survivors tended to be males, old aged, or with chronic diseases
  • Compared to survivors, non-survivors showed significantly elevated:
    • White blood cell and neutrophil count
    • Neutrophil to lymphocyte ratio (NLR)
    • Systemic immune-inflammation index (SII, defined by platelet count multiply by NLR)
    • CRP
    • Procalcitonin
    • D-dimer
  • Compared to survivors, non-survivors showed decreased:
    • Decreased red blood cell
    • Lymphocytes
    • Platelet count
  • Age, neutrophil count, platelet count, and CRP were identified as independent predictors of adverse outcome, including in sub-group analyses of those with severe or critical illness
  • Patients with markedly elevated admission CRP should be closely monitored, as this value performs well in discriminating disease severity and predicting adverse outcome in patients with COVID-19.
|2020-05-28T11:40:48-04:00May 27th, 2020|COVID-19 Literature|0 Comments

About the Author: Megan McHenry

Megan McHenry
Megan S. McHenry, MD, MS, FAAP is a pediatrician and an Assistant Professor of Pediatrics in the Ryan White Center for Pediatric Infectious Disease and Global Health at Indiana University School of Medicine. Dr. McHenry's research focuses on early childhood development in children living in resource-limited settings. This work is frequently aligned with community-engaged research and dissemination and implementation science frameworks. She primarily conducts research in collaboration with the Academic Model for Providing Access to Healthcare (AMPATH) Research Network in Kenya. Dr. McHenry currently has a career development award through the National Institutes of Health to develop a neurodevelopmental screening program for children born to HIV-infected mothers in Kenya. Dr. McHenry is also the Director of Pediatric Global Health Education and a co-Director of the Morris Green Physician-Scientist Development Program at Indiana University School of Medicine. In additional to global health lectures, she also educates residents and students on early childhood development, basic biostatistical techniques, research methodologies, and research ethics. She mentors multiple pediatric fellows, residents, and medical students interested in early childhood development within global contexts.

Get Involved with Indiana CTSI